neuronal loss in the brain, particularly in the striatum and cortex. 6 The PKC family consists of many isoforms and plays a vital role in regulating neuronal survival, proliferation, differentiation and apoptosis. 7, 8 PKC mRNA levels decrease in the brain of R6/2 transgenic HD mouse model and patients with HD. 9,10 PKC inhibition causes severe neuron death in HD Q111 transgenic mice. 11 Therefore, activating PKC pathway may be a potential method to treat HD.
In brain kynurenine pathway, tryptophan metabolizes to quinolinic acid (QA). It has been reported that the injection of QA into the striatum of rodents can induce motor, emotional and cognitive deficits in addition to significant oxidative damage and a specific loss of GABA and Ach content. 12 The excitotoxicity of QA can cause degeneration of striatal neurons, which mimic some symptoms of patients with HD in experimental animals.
Literature has reported that berberine can decrease mutant Htt level in HEK293 cells transfected with Htt-120Q and in transgenic N171-82Q HD mice. 5 However, there are no data on the actions of berberine on PKC signalling in HD animal models.
Therefore, in the present research, we want to investigate the effect of berberine on motor and cognitive deficits induced by QA injection in the striatum of mice and examine the effect of berberine on PKC signalling (PKC, GSK-3β, ERK and CREB). We also test the neuroprotective and anti-neuroinflammatory effect of berberine in vitro and in vivo.
| MATERIAL S AND ME THODS

| Materials
Berberine hydrochloride (purity ≥98%) was purchased from Dalian
Meilun Biotechnology Co., Ltd. and dissolved in double-distilled water. Quinolinic acid was purchased from Sigma-Aldrich. Go6983
(a pan-PKC inhibitor) was purchased from Selleck Chemicals. The rabbit polyclonal antibodies against GSK3β, p-GSK3β(S9) and p-PKCζ(T410) were purchased from Bioworld. The rabbit polyclonal antibodies against PKCζ were purchased from Proteintech. The rabbit polyclonal antibodies against ERK1/2, p-ERK1/2, CREB, p-CREB and BDNF, along with the mouse polyclonal antibodies against β-actin and secondary antibodies, were purchased from Santa Cruz.
| Animals
Adult male KM mice (2 months old, 22-25 g) were purchased from Liao Ning Chang Sheng Biotechnology Co., Ltd. The mice were maintained in polyacrylic cages under standard housing conditions with a 12-hour light/dark cycle. Food and water were provided ad libitum.
All of the animal studies were performed in strict accordance with the PR China legislation on the use and care of laboratory animals and the guidelines established by the Institute for Experimental
Animals at Shenyang Pharmaceutical University (Permit Number:
SYPU-IACUC-C2016-3-12-252).
| QA-induced excitotoxicity
The mice were anesthetized with 2.5% avertin (Sigma-Aldrich, USA) by i.p.. The head was fixed in a stereotactic apparatus.
Then, the mice received unilateral intrastriatal injections of QA (85 nmol/L1 μL PBS) or PBS at the following coordinates: +0.6 mm anterior to the bregma, +2.0 mm lateral to the sagittal suture and −3.0 mm ventral. The surgical operation and the QA dose selection were based on Chiarlone A et al's report, 13 which could induce motor dysfunction in mice.
| PKC inhibitor administration in mice brain
The Go6983 was continuously infused into the ventricular system at a flow rate of 0. and Bu X et al's report, 14 which can obviously inhibit PKC activity.
| Drug and treatment schedule
Experiment A: Mice were divided into four groups of ten animals each, control group, QA-injected group (model group) and QA-injected + berberine (10 or 50 mg/kg)-treated groups.
Experiment B: Mice were divided into four groups of ten animals each, QA-injected group, QA-injected + berberine (50 mg/ kg)-treated group, QA-injected + Go6983 (PKC inhibitor) group and QA-injected + Go6983 + berberine (50 mg/kg)-treated group.
Berberine or vehicle was orally administered by gavage immediately from the day of the QA injection. After the behavioural test, the mice were decapitated under ether anaesthesia and the brain was dissected. Four brains were stained with 2,3,5-triphenyltetrazolium chloride (TTC) to evaluate lesion area. Cerebral cortex was used for glutamate level and neuroinflammatory cytokines level. Striatum was used for Western blotting analysis.
The two berberine doses selection were based on Jiang et al's report, 5 which showed neuroprotective effect in mice. We also tried 90 mg/kg dose, but did not show stronger effect than the 50 mg/ kg dose. N = 10 mice/group in behavioural test. N = 4 mice/group in TTC staining. N = 5 mice/group in Western blotting analysis. N = 5 mice/group in estimation of glutamate and neuroinflammatory cytokines levels.
| Measurement of bodyweight
The bodyweights of the mice were recorded after QA injection (day 1) and on the last day of the behavioural test. Percentage change in bodyweight was calculated as (Bodyweight [last day of the behav-
| Rotarod test
The rotarod test was performed as described by Chiarlone 
| Novel object recognition test
Novel object recognition tests were performed 15-17 days after QA injection, as described in our previous report. 16 Briefly, the equipment is a square box (50 cm × 50 cm × 15 cm). First day, the mice were habituated to the equipment for 10 minutes to minimize their fear of the unfamiliar environment. On the test day, two identical objects, A1
and A2, were placed at the centre of the box. The mouse was allowed to explore the objects for 5 minutes. Then, the mouse was returned to the cage. After 1-hour rest, object A2 was replaced with a novel object B and the mouse was returned to the box to explore the objects for 5 minutes in a retention trial. After 24-hour rest, object B was replaced with another novel object C and the mouse was returned to the box to explore the objects for 5 minutes in another retention trial. The mouse directing the object with the nose at a distance less than 2 cm was defined as exploration. The exploration time for each object was recorded.
[Time spent exploring novel object/total exploration time]
was defined as the preferential index (PI).
| TTC Staining
Triphenyltetrazolium chloride staining was performed as described in our previous report. 17 After behavioural test, the mice were killed and the brains were sectioned at the QA-injected position and stained with 2% solution of TTC at 37°C in the dark for 20 minutes. The lesion area was stained white, and the normal area was red. TTC-stained sections were photographed with a digital camera, and the lesion area was analysed with an image analysis software (Image-Pro Plus 5.1).
| Estimation of glutamate level in mice
The content of glutamate was measured from cerebral cortex tissue by using a glutamate assay kit (Nanjing Jiancheng Bioengineering Institute), according to the manufacturer's protocol.
| Estimation of neuroinflammatory cytokines level in mice
The concentrations of TNF-ɑ, IL-1β and IL-18 were measured from cerebral cortex tissue by using ELISA kits (Boster), according to the manufacturer's protocol.
| Western blotting analysis
Western blotting was performed as described in our previous report. 16 Briefly, 30 μg protein was electrophoresed on 8%-12% gradient SDS-PAGE gel and transferred to PVDF membranes (Millipore).
The membranes were blocked with 5% skim milk for 2 hours at room temperature, incubated with primary antibodies: GSK3β, p-GSK3β(S9), p-PKCζ(T410) (1:500), PKCζ (1:800), ERK1/2, p-ERK1/2, CREB (1:1000), p-CREB (1:500), BDNF (1:1000), β-actin (1:1000) at 4℃ overnight, and then incubated with secondary antibodies for 2 hours at room temperature. Protein bands were visualized using an ECL kit (Kangwei Biotechnology). The intensity was quantified using densitometry with Quantity One 4.6.2 software (Bio-Rad). were pre-incubated with BV2 cells for 2 hours and then incubated with 100 ng/mL LPS for 24 hours. After that, supernatants were collected from the microglia to test the TNF-ɑ and IL-1β levels by using ELISA kits (Boster).
| Cell viability
| PKC siRNA Transfections
Control siRNA/60 nmol/L PKC siRNA (M-091560-01-0005, Dharmacon) was transfected into BV2 cells using Lipofectamine 2000
(Invitrogen) according to the manufacturer's protocol. After 24 hours, BV2 cells were treated with berberine (1, 2.5 and 5 μmol/L) for an additional 2 hours. Subsequently, the cells were incubated with 100 ng/ mL LPS for 24 hours. After that, supernatants were collected from the microglia to test the TNF-ɑ and IL-1β levels by using ELISA kits (Boster).
| BV2-conditioned medium treatment
After treatment with LPS and berberine, the medium was collected and centrifuged at 12 000 g for 5 minutes to remove cellular debris. 18 5 × 10 4 PC12 cells per well were planted in 96-well plates.
The conditioned medium was added into PC12 cells for 24 hours, followed by the cell viability analysis as described above.
| Statistical analysis
The data were analysed using SPSS 21.0. The statistical significance was determined using one-way ANOVA followed by Fisher's LSD multiple comparisons test with homogeneity of variance or Dunnett's T3 test with heterogeneity of variance. The Kruskal-Wallis test was used to analyse the data, which was not normally distributed. Experimental data are represented as means ± SD or SEM. A P < 0.05 indicates statistical significance.
| RE SULTS
| Effects of berberine on bodyweight, motor and cognitive impairments induced by intrastriatal QA injection
QA injection reduced bodyweight on the last day of the behavioural test compared with the control group (F(3, 36) =2.893, P < 0.05, post hoc, P < 0.05, Figure 1A ). Berberine (50 mg/kg) treatment resulted in F I G U R E 1 Effects of berberine on bodyweight and behavioural test in QA-injected mice. A, QA-injected mice exhibited a decrease in bodyweight compared with control mice. B, QA-injected mice exhibited impairment of motor coordination in rotarod test. C-D, QA injection impaired memory recall and visual recognition in novel object recognition test. E-F, No significant differences in the total exploring time of 1 or 24 hours were found among the groups in novel object recognition test. All these effects were attenuated by treatment with berberine.
The results of bodyweight are expressed as the mean ± SEM. The results of the behavioural test are expressed as the mean ± SD. n = 10 mice/group; # P < 0.05, ## P < 0.01 vs control; *P < 0.05, **P < 0.01 vs model though not statistically significant (P = 0.141, Figure 1A ).
The rotarod test was performed in mice to evaluate the motor coordination after QA administration. Compared with the control group, intrastriatal QA injection shortened the latency to fall values on days 7 and 14 after QA injection (P < 0.01, Figure 1B ). Berberine (50 mg/kg) treatment improved rotarod performance (P < 0.05, Figure 1B ).
The novel object recognition test was performed in mice individually to evaluate the recall memory after QA administration. The PI for novel object B was decreased in the QA group (F(3, 36) =4.895, P < 0.01, post hoc, P < 0.01, Figure 1C ), indicating that QA injection impaired memory recall and visual recognition. 50 mg/kg berberine attenuated QA injection-induced decrease of PI (P < 0.01, Figure 1C ). Similar results were observed with novel object C. The PI for QA group was decreased (F(3, 36) =8.079, P < 0.01, post hoc, P < 0.01, Figure 1D ). 50 mg/kg berberine prevented these decreases (P < 0.05, Figure 1D ). No significant differences in the total exploring time of 1 or 24 hours were found among the groups (1 hour: F(3, 36)=1.404, P = 0.257; 24 hours: F(3, 36)=1.491, P = 0.233, Figure 1E , F). Therefore, we believed that the exploration of the objects did not interfere by motor impairment. Literature reported that QA could induce motor and spatial memory impairments from 3 days to 10 weeks after intrastriatal injection. 13, 19, 20 And treatment with berberine for 14 days significantly prevented cognitive deficits induced by Aβ or scopolamine. 21, 22 Based on the above studies, we chose days 7 and 14 after QA injection to test motor impairment and days 15-17 after QA injection to test cognitive impairment.
| Effects of berberine on QA-induced motor and cognitive impairments with Go 6983 infusion
There was no significant difference of QA group and QA + Go 6983 F I G U R E 2 Effects of berberine on QAinduced motor and cognitive impairments with Go6983 infusion. Go6983 infusion neither alleviated nor worsened cognitive and motor function (A-C). But, the positive effect of berberine on mice in novel object recognition test (A) and rotarod test (C) was partially blocked by Go6983 infusion. The results of the behavioural test are expressed as the mean ± SD. n = 10 mice/ group; *P < 0.05, **P < 0.01 
| Effects of berberine on QA-induced striatal lesion area
Brain striatal lesion size was evaluated by TTC staining at the end of the novel object recognition test. There was brain infarct injury after QA injection in both the striatum and cortex. The lesion area percentage was 19.52 ± 5.72% in QA group and 18.81 ± 3.41% in QA + Go 6983 group (F(3, 12) =10.177, P < 0.01, post hoc, P = 0.806, Figure 3 ). Berberine (50 mg/kg) treatment prevented this brain injury (P < 0.01). Compared with QA + berberine group, the neuroprotective effect of berberine was partially blocked by Go 6983 infusion (P < 0.05, Figure 3 ).
F I G U R E 4
Effect of berberine on the expressions of PKC and its downstream molecules in the striatum. Berberine (50 mg/kg) increased the phosphorylation levels of PKC, GSK-3β, ERK and CREB, and the expression level of BDNF. All of the results are expressed as the mean ± SEM. n = 5/group; # P < 0.05, ## P < 0.01 vs control; *P < 0.05, **P < 0.01 vs model Treatment with berberine increased the p-PKC, p-ERK, p-CREB, p-GSK-3β, and expression level of BDNF (P < 0.05, Figure 4 ).
| Effect of berberine on the content of glutamate and proinflammatory cytokines
Huntington's disease animal models showed an increase level of glutamate. Intrastriatal administration of QA enhanced the glutamate level in cerebral cortex (F(3, 16) =5.058, P < 0.05, post hoc, P < 0.01, Figure 5A ). 50 mg/kg berberine decreased glutamate level in cerebral cortex (P < 0.05, Figure 5A ). 
| Effect of berberine on LPS-induced proinflammatory cytokines release in BV2 cells
Berberine did not affect BV2 cell viability at concentrations from 0.5 μmol/L to 5 μmol/L ( Figure 6A ). Therefore, we used 1, 2. cells. This protective effect was partly blocked by Go6983 (a PKC inhibitor), but with no significance (Figure 6C-F) . This protective effect was significantly blocked by PKC siRNA (P < 0.05, Figure 6C -F).
These results indicated that the anti-neuroinflammatory effect of berberine was partly by activating PKC.
F I G U R E 5
Effect of berberine on glutamate and neuroinflammatory cytokines levels in cerebral cortex. QA injection enhanced the glutamate level (A) and the content of TNF-ɑ (B), IL-1β (C) and IL-18 (D). These effects were attenuated by treatment with berberine. All of the results are expressed as the mean ± SD. n = 5/group; ## P < 0.01 vs control; *P < 0.05, **P < 0.01 vs model 
| Effect of berberine on glutamate-induced PC12 cells death and microglia-mediated neurotoxicity
Berberine did not affect PC12 cell viability at concentrations from 0.5 μmol/L to 15 μmol/L ( Figure 7A ). Incubation with glutamate significantly decreased cell viability (58.93 ± 9.15%, P < 0.01, Figure 7A ). Berberine significantly increased cell viability at 5 μmol/L (86.83 ± 11.71%, P < 0.05, Figure 7B ). Go6983 blocked the neuroprotective effect of berberine (cell viability: 1 μmol/L, 59.31 ± 9.10%; 5 μmol/L, 69.77 ± 4.62%; 10 μmol/L, 68.34 ± 14.59%, Figure 7B ). These results indicated that the neuroprotective effect of berberine was partly by activating PKC.
Conditioned medium (CM) from LPS-treated BV2 cells signifi-
cantly decreased the viability of PC12 cells. The CM from berberine-treated BV2 cells could prevent PC12 cell death (cell viability:
1 μmol/L, 81.73 ± 7.62%; 2.5 μmol/L, 84.56 ± 5.17%; 5 μmol/L, 91.28 ± 5.54%, Figure 7C ). Therefore, we believed that the 
| D ISCUSS I ON
Berberine has been showed to attenuate cognitive deficits in dementia animal models and improving motor deficits in Parkinson's disease animal models. 24, 25 These positive effects in cognitive and motor behaviour are regulated by many factors, such as a decrease in ROS, neuron and synapse apoptosis. Jiang et al first reported
that berberine could attenuate motor impairment and prolong the survival of transgenic N171-82Q HD mice. 5 However, the underlying mechanisms of berberine against HD are still not fully understood.
QA, a product of tryptophan metabolism in the kynurenine pathway, can activate NMDA receptors to produce excitotoxicity and cause inflammation, oxidative stress, lipid peroxidation and mitochondrial dysfunction. The injection of QA into the striatum of rodent or primate models is frequently used to evaluate the ability of candidate compounds in minimizing the striatal lesion and preventing motor and cognitive deficits that are associated with HD pathogenesis. 26 In this study, motor deficits were evaluated by rotarod test. QA injection caused motor incoordination, which is partially in accordance with the findings of some studies. 13, 27 After which is caused by neuronal and synapse loss. 28 In this study, we used the novel object recognition test to evaluate the effect of berberine on recall memory. 29 The injection of QA induced persistent and significant learning and memory deficits, which were partially in accordance with findings of other studies. 30, 31 The recall memory of the mice was improved by berberine treatment. Progressive bodyweight decrease is a common hallmark in patients with HD.
In our study, intrastriatal QA administration resulted in a drastic decrease in bodyweight, which was attenuated by berberine.
Therefore, we believe that this finding elucidates potential uses of berberine to cure HD.
PKC is important for regulating neuronal survival. Activated PKC shows a neuroprotective effect in neurodegenerative diseases. 32 Some publications reported that inhibition of PKC isoform ζ could induce apoptosis in neurons and cancer cell lines 33 as PKC ζ, the downstream effector of PI3K, promotes cell proliferation and survival. 34 Glutamate, the most important excitatory neurotransmitter, mediated excitotoxicity to induce brain tissue damages. NMDA receptors are hyperactive in striatal neurons of many HD animal models. 41 In this study, QA as an NMDA receptor agonist significantly enhanced glutamate-mediated excitotoxicity and induced serious neuronal degeneration. Berberine significantly decreased the glutamate level in cerebral cortex. Furthermore, in vitro study, we found that berberine decreased the PC12 cell and BV2 cell deaths induced by glutamate, and PKC inhibitor could block the neuroprotective effect of berberine.
In conclusion, berberine is protective against intrastriatal injection of QA-induced motor and cognitive impairments. Moreover, berberine regulates PKC and its downstream molecules, GSK-3β, ERK and CREB;
increases BDNF levels; further, attenuates proinflammatory cytokine release; and alters glutamate levels ( Figure 8 ). Taken together, berberine showed neuroprotective effect against QA-induced acute neurotoxicity by activating PKC and its downstream molecules. However, it remains unclear how berberine activates PKC, and whether berberine can directly be associated with PKC to regulate its function. These questions require more in-depth studies to clarify.
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